Osteonecrosisof the jaw in osteooncology;Kieferosteonekrosen in der osteoonkologie

Osteologie

Volumn 21, Issue 3, 2012, Pages 193-200

  Diel, Ingo J ^a  

^a Institut für Gynäkologische Onkologie   (Germany)

Author keywords

Bisphosphonates; Bone metastases; Denosumab; ONJ; Osteonecrosis of the jaw; Osteoprotection

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; FRACTURE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; MORBIDITY; MULTIPLE MYELOMA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUALITY OF LIFE; SOLID TUMOR; TREATMENT DURATION;

EID: 84867621233     PISSN: 10191291     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621685     Document Type: Article

References (37)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev 2002; 2: 584-593. (Pubitemid 37328925)
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature Rev 2002; 2: 563-572. (Pubitemid 37328923)
3. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-3571. (Pubitemid 32734171)
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
5. Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanism of action of bisphosphonates. Bone 1999; 24: 73S-79S.
6. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS. J Bone Miner Res 1998; 13: 581-558.
7. Selander KS, Mönkkönen J, Karhukorpi EK et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50: 1127-1138. (Pubitemid 26384851)
8. Paterson AHG, Powles TJ, Kanis JA et al. Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65. (Pubitemid 23059975)
9. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-1791. (Pubitemid 26412396)
10. Hortobagyi GN, Theriault RL, Lipton A et al. Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-2044. (Pubitemid 28265038)
11. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405. (Pubitemid 37185286)
12. Body JJ, Diel IJ, Lichinitser M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with with metastatic bone disease; results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137. (Pubitemid 38496803)
13. Diel IJ, Body JJ, Lichinitser MR et al. Improved quality of life for long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004; 40: 1704-1712. (Pubitemid 38902906)
14. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314-3321.
15. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial. Cancer J 2001; 7: 377-387. (Pubitemid 33759002)
16. Rosen LS, Gordon DH, Dugan W et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43. (Pubitemid 37553537)
17. Van Poznak CH, Temin GC, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.
18. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342. (Pubitemid 40852708)
19. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176. (Pubitemid 28180851)
20. Hofbauer LC, Heufelder AE. Role of receptor activator of nuklear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253. (Pubitemid 32646379)
21. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind 3 study. J Clin Oncol 2010; 35: 5132-5139.
22. Henry DH, Costa L, Goldwasser F et al. Randomized double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
23. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised double-blind study. Lancet 2011; 377: 813-822.
24. Lipton A et al. Comparison of Denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients : An integrated analysis of 3 pivotal trials. Ann Oncol 2010; 21 (Suppl. 8): Abstract P 1249.
25. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117. (Pubitemid 37064711)
26. Carter, GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003; 48: 268.
27. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofacial Surg 2004; 62: 763-764. (Pubitemid 38736457)
28. Ruggiero SL, Mehrota B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534. (Pubitemid 38542516)
29. Arzneimittelkommission der deutschen Ärzteschaft. Osteonekrosen des Kiefers unter Bisphosphonaten. Dtsch Ärzteblatt 2004; 101: A 2203.
30. Grötz KA und Diel IJ. Fortbildungsreihe Supportivtherapie: Osteonekrose des Kiefers unter Bisphosphonat-Langzeittherapie. Im Focus Onkologie 2005; 3: 52-55.
31. Felsenberg D, Hoffmeister B, Amling M et al. Kiefernekrosen nach hoch dosierter Bisphosphonat - therapie. Dtsch Ärzteblatt 2006; 103: A 3078-3080.
32. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761. (Pubitemid 46780635)
33. Saad F, Brown JE, van Poznack C et al. Incidence, risk factors and outcomes of osteonecrosis of the jaw : integrated analysis from three blinded active-contolled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
34. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with cas-tration- resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
35. Coleman R, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
36. Diel IJ, Fogelman I, Hoffmeister B et al. Pathophysiology, risk factors and management of bisphos-phonate- associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-amino-bisphosphonates? Crit Rev Oncol 2007; 64: 198-207. (Pubitemid 350030960)
37. Paterson AHG, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (NSABP-project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.